Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Although in vitro models have been a cornerstone of anti-cancer drug development, their direct applicability to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance (MDR) transcriptome of six cancer types, in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples, either containing >75% tumor cells or microdissected. The MDR transcriptome was determined a priori based on an extensive curation of the literature published during the last three decades, which led to the enumeration of 380 genes. No correlation was found between clinical samples and established cancer cell lines. As expected, we found up-regulation of genes that would facilitate survival across all cultured cancer cell lines evaluated. More troubling, however, were data showing that all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model. Although cultured cells can be used to study many aspects of cancer biology and response of cells to drugs, this study emphasizes the necessity for new in vitro cancer models and the use of primary tumor models in which gene expression can be manipulated and small molecules tested in a setting that more closely mimics the in vivo cancer microenvironment so as to avoid radical changes in gene expression profiles brought on by extended periods of cell culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Established cell cultures have been the predominant research models of osteosarcoma for decades, but the culture-related alterations that cell lines acquire over tens and sometimes hundreds of passages 220,221 led to the development of systems for propagating osteosarcoma tumours 220,221 by creating libraries of primary tumour cell cultures and patient-derived xenografts (PDXs).”
From Osteosarcoma (2022) · cites this paper as [220]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, it has been shown that established cell lines do not capture disease heterogeneity across patients and hence are lacking in clinical relevance (Gillet et al., 2011; Yee et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Gillet et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our results confirm the low translational relevance of established cancer cell lines for the identification of clinical anti-cancer drug resistance [38].”
From Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Among those genes, ATP-binding cassette (ABC) transporters, a superfamily of 48 highly homologous members classified in seven subfamilies, have an important role in the pleiotropic mechanisms mediating MDR by exporting chemotherapeutic agents from the cell (14, 15).”
BackgroundSelf-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · cited 1×
“It is clearly possible that p53 pathway activation results from selective pressure in the tissue culture environment, in turn causing the up-regulation of stress response genes across all cell lines and contributing to the uniformity of the MDR gene expression pattern (35).”
BackgroundO'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Chemosensitivity prediction by transcriptional profiling
Staunton, J. E., Slonim, D. K., Coller, H. A., Tamayo, P., Angelo, M. J., Park, J., Scherf, U., Lee, J. K., Reinhold, W. O., Weinstein, J. N., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191368598 · Cited by 684
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
Transcriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Microarray Analysis and Tumor Classification
Quackenbush, J. (2006) · New England Journal of Medicine · doi:10.1056/nejmra042342 · Cited by 455
Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 453
A complex barcode underlies the heterogeneous response of p53 to stress
Murray-Zmijewski, F., Slee, E. A., & Lu, X. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2451 · Cited by 420
A global map of human gene expression
Lukk, M., Kapushesky, M., Nikkilä, J., Parkinson, H., Goncalves, A., Huber, W., Ukkonen, E., & Brazma, A. (2010) · Nature Biotechnology · doi:10.1038/nbt0410-322 · Cited by 350
Chemotherapy-induced resistance by ATP-binding cassette transporter genes
GILLET, J., EFFERTH, T., & REMACLE, J. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.05.002 · Cited by 337
Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics
Calcagno, A. M., Salcido, C. D., Gillet, J.-P., Wu, C.-P., Fostel, J. M., Mumau, M. D., Gottesman, M. M., Varticovski, L., & Ambudkar, S. V. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq361 · Cited by 279
Gillet, J.-P., Efferth, T., Steinbach, D., Hamels, J., de Longueville, F., Bertholet, V., & Remacle, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1978 · Cited by 222
Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., & Hamilton, T. C. (1997) · PubMed · Cited by 178
Chapuy, B., Koch, R., Radunski, U., Corsham, S., Cheong, N., Inagaki, N., Ban, N., Wenzel, D., Reinhardt, D., Zapf, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.103 · Cited by 162
Molecular Concepts Analysis Links Tumors, Pathways, Mechanisms, and Drugs
Rhodes, D. R., Kalyana-Sundaram, S., Tomlins, S. A., Mahavisno, V., Kasper, N., Varambally, R., Barrette, T. R., Ghosh, D., Varambally, S., & Chinnaiyan, A. M. (2007) · Neoplasia · doi:10.1593/neo.07292 · Cited by 142
Wolf, C. R., Hayward, I. P., Lawrie, S. S., Buckton, K., McIntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R., & Smyth, J. F. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390607 · Cited by 135
ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid Leukemia
Steinbach, D., Gillet, J., Sauerbrey, A., Gruhn, B., Dawczynski, K., Bertholet, V., de Longueville, F., Zintl, F., Remacle, J., & Efferth, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2587 · Cited by 123
Wang, B., Howel, P., Bruheim, S., Ju, J., Owen, L. B., Fodstad, O., & Xi, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017167 · Cited by 120
Gene-expression profiling in epithelial ovarian cancer
Konstantinopoulos, P. A., Spentzos, D., & Cannistra, S. A. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1178 · Cited by 115
Barton, D. L., Wender, D. B., Sloan, J. A., Dalton, R. J., Balcueva, E. P., Atherton, P. J., Bernath, A. M., DeKrey, W. L., Larson, T., Bearden, J. D., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk149 · Cited by 111
Shen, D., PASTAN, I., & Gottesman, M. M. (1998) · PubMed · Cited by 105
Liang, X., Shen, D., Garfield, S. H., & Gottesman, M. M. (2003) · PubMed · Cited by 95
Chapuy, B., Panse, M., Radunski, U., Koch, R., Wenzel, D., Inagaki, N., Haase, D., Truemper, L., & Wulf, G. G. (2009) · Haematologica · doi:10.3324/haematol.2009.008631 · Cited by 91
How accurate are cancer cell lines?
Borrell, B. (2010) · Nature · doi:10.1038/463858a · Cited by 84
Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer
Gillet, J.-P., & M. Gottesman, M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163931 · Cited by 72
Simon, R. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.009 · Cited by 70
Efferth, T., Gillet, J., Sauerbrey, A., Zintl, F., Bertholet, V., de Longueville, F., Remacle, J., & Steinbach, D. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0086 · Cited by 68
Models of ovarian cancer—Are we there yet?
Garson, K., Shaw, T. J., Clark, K., Yao, D., & Vanderhyden, B. C. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.03.019 · Cited by 65
Do predictive signatures really predict response to cancer chemotherapy?
Borst, P., & Wessels, L. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14326 · Cited by 62
Molecular characterization of ovarian cancer by gene-expression profiling
Gómez-Raposo, C., Mendiola, M., Barriuso, J., Hardisson, D., & Redondo, A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.03.012 · Cited by 50
Langmann, T., Mauerer, R., & Schmitz, G. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059774 · Cited by 49
Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions
Gillet, J.-P., Wang, J., Calcagno, A. M., Green, L. J., Varma, S., Bunkholt Elstrand, M., Trope, C. G., Ambudkar, S. V., Davidson, B., & Gottesman, M. M. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200240a · Cited by 47
Maeda, T., Tashiro, H., Katabuchi, H., Begum, M., Ohtake, H., Kiyono, T., & Okamura, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602662 · Cited by 38
Orina, J. N., Calcagno, A. M., Wu, C., Varma, S., Shih, J. H., Lin, M., Eichler, G. S., Weinstein, J. N., Pommier, Y. G., Ambudkar, S. V., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0256 · Cited by 38
Animal Models of Ovarian Cancer
Connolly, D. C. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-98094-2_17 · Cited by 31
Apoptotic pathways of epothilone BMS 310705
Uyar, D. S., Takigawa, N., Mekhail, T. M., Grabowski, D., Markman, M., Lee, F. Y., Canetta, R. M., Peck, R., Bukowski, R. M., & Ganapathi, R. N. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00481-5 · Cited by 19
DualChip®microarray as a new tool in cancer research
Gillet, J., de Longueville, F., & Remacle, J. (2006) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.6.3.295 · Cited by 12
Cited by
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
“Key methodologic aspects of selected PDX collections Reference Tumor type Available models Origin Procurement Processing Mice strain Implantation site Engraftment rate (28) CRC 130 Metastasis Surgery Fresh tumor pieces in Matrigel NOD/SCID s.c. 87% (29) CRC 54 Primary (35) Metastasis (19) Surgery Fresh tumor pieces Nu…”
BackgroundInfluentialEvaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
“Top right panels: neighbourhoods (1) of the top cell lines in our analysis, (2) of cell line IGROV1, and (3) of cell line A2780.”
BackgroundShen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955
“These inhibitors may have potential for future clinical application.”
BackgroundSelf-citationBeird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
The Clinical Relevance of Cancer Cell Lines
Gillet, J.-P., Varma, S., & Gottesman, M. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt007 · Cited by 599
“These mechanisms can act individually or synergistically, leading to MDR, in which cells become resistant to a variety of structurally and mechanistically unrelated drugs (28).”
BackgroundMethodResultInfluential
Metadata
- Authors
- Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., Padmanabhan, R., Davidson, B., Ganapathi, R., Sood, A. K., Rueda, B. R., Ambudkar, S. V., & Gottesman, M. M.
- Affiliations
- National Cancer Institute (UA)
- National Institutes of Health (US)
- Biophase Systems, Fremont, CA 94539;
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-11-08
- Volume
- 108
- Issue
- 46
- Pages
- 18708-18713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3219108
- OpenAlex
- W2018044006
- Cited by
- 477
- References
- 46
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 43 · 2022: 28 · 2021: 34 · 2020: 41 · 2019: 45 · 2018: 33 · 2017: 46 · 2016: 40 · 2015: 40 · 2014: 20 · 2013: 29 · 2012: 16
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Namur (submittedVersion)
- Funders
- Georgetown University
- Karolinska Institutet
- National Institutes of Health
- Lombardi Comprehensive Cancer Center, Georgetown University
- National Cancer Institute (NCI-60)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- cancer cell lines, multidrug resistance, drug resistance mechanisms, xenografts, 3D cell culture, gene expression profiles, in vitro tumor model, tumor microenvironment
- MeSH terms
- Antineoplastic Agents, Cell Survival, Drug Screening Assays, Antitumor, Female, Humans, Ovarian Neoplasms, Ovary, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Cell Line, Tumor, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.